Tokyo, Jan. 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060280) titled 'Effect of dotinurad on proteinuria in patients with hyperuricemia' on Jan. 8.
Study Type:
Observational
Primary Sponsor:
Institute - Ibaraki prefectural central hospital,Ibraki cancer center
Condition:
Condition - Patients with hyperuricemia and proteinuria
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the effect of dotinurad on reducing proteinuria in patients with hyperuricemia and proteinuria.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who visited the outpatient department of Ibaraki Prefectural Central Hospital/Ibaraki Regional Cancer Center between April 2021 and September 2024 and were prescribed dotinurad for hyperuricemia were included. Among these, patients for whom serum uric acid levels, serum creatinine levels, and UPCR could be evaluated at 1, 3, 6, and 12 months post-administration and whose UPCR was 0.15 g/gCr or higher were included.
Key exclusion criteria - Patients who had a new intervention of other drugs after the start of dothinurad were excluded.
Target Size - 23
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2021 Year 04 Month 01 Day
Date of IRB - 2025 Year 12 Month 09 Day
Anticipated trial start date - 2021 Year 04 Month 01 Day
Last follow-up date - 2025 Year 09 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068956
Disclaimer: Curated by HT Syndication.
